Skip to content

Clinical Observation and Related Mechanism of Treatment of Depression Heat and Phlegm Conjugation Type of Graves' Disease by Jiakangping Granule

Clinical Observation and Related Mechanism of Treatment of Depression Heat and Phlegm Conjugation Type of Graves' Disease by Jiakangping Granule

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002198
Enrollment
Unknown
Registered
2025-11-17
Start date
2025-11-15
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

Treatment group:Methimazole tablets orally in combination with Methylthiouracil granules orally.
Control Group:Methimazole tablets orally in combination with Propylthiouracil granules placebo orally.

Sponsors

Capital Medical University Affiliated Beijing Shijitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for Graves' disease in Western medicine. (2) Meets the diagnostic criteria for Yutie Tanjiezhen syndrome in traditional Chinese medicine. (3) Aged 18 to 70 years old, both males and females are eligible. (4) Able to understand and comply with the research procedures, voluntarily participate in this study, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: If any of the following conditions apply, the patient will be excluded from participating in this study: 1. Patients with hyperthyroidism caused by diseases other than Hashimoto's thyroiditis or patients with autoimmune diseases; 2. Patients with thyroid enlargement compressing adjacent organs; 3. Patients with thyrotoxic crisis or a history of 131I treatment; 4. Pregnant women, breastfeeding women, or women planning pregnancy; 5. Patients allergic to the drugs used in this study; 6. Patients with severe underlying diseases of the heart, brain, liver, kidneys, or hematopoietic system, or severe metabolic disorders; 7. Patients with severe trauma or major surgery that may affect the observation and assessment of indicators; 8. Patients with mental illness; 9. Patients who have received other clinical trial treatments within the past three months.

Design outcomes

Primary

MeasureTime frame
Thyroid Function Indicators;Immune factors;TCM Syndrome Score;

Secondary

MeasureTime frame
The degree of goiter;Transcriptomics biomarkers;metabolomics biomarkers;

Countries

China

Contacts

Public ContactJiang Min

Capital Medical University Affiliated Beijing Shijitan Hospital

jiangm1965@sina.com13311108797

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026